High graft protection and low incidences of infections, malignancies and other adverse effects with intraoperative high dose ATG-induction: A single centre cohort study of 760 cases

Annals of Transplantation

Volumn 18, Issue 1, 2013, Pages 9-22

  Kaden, Jürgen ^a   Völp, Andreas ^b   Wesslau, Claus ^a  

^a VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^b Psy Consult Scientific Services   (Germany)

Author keywords

Adverse effects; Antilymphocyte globulins; ATG fresenius; ATG induction; Graft survival; Kidney transplantation; Patient survival

Indexed keywords

AZATHIOPRINE; CD45 ANTIGEN; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIGEN PP65; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PANEL REACTIVE ANTIBODY; PREDNISOLONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; BODY WEIGHT; CHRONIC PATIENT; COHORT ANALYSIS; COLD ISCHEMIA; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DRUG DOSE REDUCTION; DRUG INFUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; GRAFT SURVIVAL; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; LEUKOCYTE; LEUKOPENIA; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PEROPERATIVE CARE; RETROSPECTIVE STUDY; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTOPENIA;

ADULT; ANTILYMPHOCYTE SERUM; AZATHIOPRINE; COHORT STUDIES; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRAOPERATIVE PERIOD; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; STEROIDS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84874751605     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.883792     Document Type: Article

References (40)

1. Kaden J, May G, Schönemann C et al: Effect of ATG prophylaxis in sensitized and non-sensitized kidney graft recipients. Transplant Int, 1992; 5(Suppl.1): S75-78
2. Kaden J: Optimal management of induction therapy with ATG in kidney allograft recipients. Int J Immunotherapy, 1999; 15: 115-124
3. Kaden J, May G, Völp A, Wesslau C: Improved long-term survival after intra-operative single high-dose ATG-Fresenius induction in renal transplantation: A single centre experience. Ann Transplant, 2009; 14(3): 7-17
4. Saudek F, Adamec M, Kožnarová, et al: Low rejection rate with high-dose ATG bolus therapy in simultaneous pancreas and kidney transplantation. Transplant Proc, 2001; 33: 2304-6
5. Yussim A, Shapira Z: Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation - a prospective, randomize study. Transplant Int, 2000; 13: S293-94
6. Samsel R, Pliszczynski J, Chmura A et al: Safety and Efficacy of high dose ATG bolus administration on revascularization in kidney graft patients - long term results. Ann Transplant, 2008; 13: 32-39
7. Sheashaa HA, Hamdy AF, Bakr MA et al: Longterm evaluation of single bolus high dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation. Int Urol Nephrol, 2008; 40: 515-20
8. Schulz T, Konzack J, Büsing M: Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. Transplant Proc, 1999; 31: 591-92
9. Kyllönen LE, Eklund BH, Pesonen EJ, Salmela KT: Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: Efficacy and safety. Transplantation, 2007; 84: 75-82
10. Kaden J, May G, Völp A, Wesslau C: Factors impacting short and long-term kidney graft survival: Modifcation by single intra-operative high-dose induction with ATG-Fresenius. Ann Transplant, 2011; 16: 81-94
11. Kaden J, May G, Völp A, Wesslau C: Efficacy and safety of the intra-operative high-dose induction with ATG-Fresenius in older kidney graft recipients. Transplantationsmedizin, 2011; 23: 215-22
12. Kaden J, May G: Zuverlässiger und schneller CMV-pp65-Antigennachweis in peripheren Blutleukozyten mit dem CINAkit bei Patienten nach Nierentransplantation. Transplantationsmedizin, 1998; 10: 59-68 [in German]
13. Bock HA, Gallati H, Zürcher RM et al: A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius versus OKT3 after renal transplantation. Transplantation, 1995; 59: 830-40
14. Neuhaus P, Bechstein WO, Blumhardt G et al: Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation, 1993; 55: 1320-27
15. Yang S-L, Wang D, Wu W-Z et al: Comparison of single bolus ATG and basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolomus-based immunosuppressive regimen. Transplant Immunol, 2008; 18: 281-85
16. Ulrich F, Niedzwiecki S, Pascher A et al: Longterm outcome of ATG vs. basiliximab induction. Europ J Clin Invest, 2011; 41: 971-78
17. Kaden J, May G, Müller P et al: Intraoperative high-dose anti-T-lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival. Transplant Proc, 1995; 27: 1060-61
18. St. Hillier Y, Hory B, Racadot E, et al: Systemic IL-10 release after a single pre or perioperative large dose of ATG-Fresenius in human kidney transplantation. J Am Soc Nephrol, 1994; 5: 1035
19. Faggian G, Forni A, Milano AD et al: Antithymocyte globulin induction therapy in heart transplantation: prospective randomized study of high vs standard dosage. Transplant Proc, 2010; 42: 3679-87
20. Kaden J, Eichler S, May G, Strobelt V: The ATG bolus does not induce a persistent inversion of the CD4/8 ratio. Transplant Proc, 2002; 34: 2379-81
21. Müller TF, Grebe SO, Neumann C et al: Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation, 1997; 64: 1432-37
22. Lange H, Müller TF, Ebel H et al: Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional theraqpy for immediate graft function. Transplant Int, 1999; 12: 2-9
23. Oertel M, Sack U, Kohlhaw K et al: Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study. Transplant Int, 2002; 15: 463-71
24. Benitez CE, Puig-Pey I, López M et al: ATGFreseniua treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant, 2010; 10: 2296-304
25. Ducloux D, Courivaud C, Bamoulid J et al: Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation. J Am Soc Nephrol, 2010; 21: 868-75
26. Engels EA, Pfeiffer RM, Fraumeni Jr JF et al: Spectrum of cancer risk among US solid organ transplant recipients. JAMA, 2011; 17: 1891-901
27. Apel H, Walschburger-Zorn K, Wulich B, Engehausen DG: Maligne Tumoren nach Nierentransplantation am Transplantationszentrum Erlangen-Nürnberg. Transplantationsmedizin, 2008; Suppl II; 130 [in German]
28. Kauffman HM, Cherikh WS, McBride MA et al: Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transplant Int, 2006; 19: 607-20
29. Opelz G, Naujokat C, Daniel V et al: Disassociation between risk of graft loss and risk of NonHodgkin-Lymphoma with induction agents in renal transplant recipients. Transplantation, 2006; 81: 1227-33
30. Sia IG, Paya CV: Infectious complications following renal transplantation. Surg Clin NA, 1998; 78: 95-110
31. Krogsgaard K, Boesgaard S, Aldershvile J et al: Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte induction therapy. Scand J Infect Dis, 1994; 26: 239-47
32. Kaden J, Zenker S, Eichler C et al: Das CMVInfektionsund Erkrankungsrisiko nach Nierentransplantation. Allerg Immunol, 1991; 37: 47-58 [in German]
33. Pescovitz MD: Valganciclovir. Am J Transplant, 2010; 10: 1359-64
34. Witzke O, Hauser IA, Bartels M et al: Valganciclovir prophylaxis versus preemptive therapy in Cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation, 2012; 15: 61-68
35. Kaden J, Schneider U, Schröder K et al: Effektivität und Kosten der Immunglobulinprophylaxe zur Prävention von Cytomegalieviruserkrankungen nach Nierentransplantation. Pädiatr Grenzgeb, 1993; 31: 471-85 [in German]
36. Nampoory MRN, Abdulhalim M, Johny KV et al: Bolus anti-Thymocyte-globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-Interleukin-2 receptor antibody induction. Transplant Proc, 2002; 34: 2916-19
37. Ducloux D, Kazory A, Challier B et al: Longterm toxicity of antithymocyte globulin induction may vary with choice of agents: a single-center retrospective study. Transplantation, 2004; 77: 1029-33
38. Kim MJ, Tsinalis D, Franz S et al: ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial. Ann Transplant, 2008; 13: 21-27
39. Mota C, Martins L, Costa T et al: Nineteen years of experience utilizing anti-T-lymphocyte globulin induction in pediatric kidney transplantation. Ann Transplant, 2010; 15: 84-91
40. Opelz G, Daniel V, Naujokat C et al: Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol, 2007; 8: 212-18